The Journal of Immunology, Vol 155, Issue 6 3124-3134, Copyright © 1995 by American Association of Immunologists

ARTICLES

Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses

GA Watson and DM Lopez
Department of Microbiology and Immunology, University of Miami School of Medicine, 33101, USA.

Splenic T cells from BALB/c mice bearing mammary adenocarcinomas initially demonstrate a primed response to tumor-associated Ags (TAA), which declines to presensitization levels within 4 wk after tumor implantation. Associated with this decline in responses to TAA is the expansion of a subpopulation of Mac-1+ 2+ splenic macrophages (M phi). These Mac-1+ 2+ cells present TAA inefficiently to normal T cells primed to TAA by footpad injection, as compared with the Ag presenting ability of M phi from normal mice. The addition of anti-I-Ed, but not anti-I-Ad, Ab blocked the ability of Ag-pulsed Mac-1+ 2+ cells to present TAA to primed T cells. The converse was observed with macrophages from normal mice. However, presentation of human gamma- globulin or OVA was restricted by I-Ad molecules when APC from normal mice or tumor bearers were used, although less efficiently in the latter. Using cell depletion techniques, it was determined that the I- Ed-restricted presentation preferentially expanded CD8+ T cells, and not CD4+ cells, as was the case for I-Ad-restricted normal macrophages. These CD8+ cells were poor effectors of cytotoxicity against tumor cells; instead they down-regulated the proliferative activity of T cells. Limiting dilution assays indicated that Mac-1+ 2+ macrophages preferentially present TAA to a low frequency inhibitory T cell population that expanded and inhibited further responses to TAA. Thus, alterations of Ag presentation in tumor bearers may help the tumor to subvert potential beneficial host responses and allow the progression of the neoplastic process.

This article has been cited by other articles:

				S. Kusmartsev and D. I. Gabrilovich STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion J. Immunol., April 15, 2005; 174(8): 4880 - 4891. [Abstract] [Full Text] [PDF]

				T. Ghansah, K. H. T. Paraiso, S. Highfill, C. Desponts, S. May, J. K. McIntosh, J.-W. Wang, J. Ninos, J. Brayer, F. Cheng, et al. Expansion of Myeloid Suppressor Cells in SHIP-Deficient Mice Represses Allogeneic T Cell Responses J. Immunol., December 15, 2004; 173(12): 7324 - 7330. [Abstract] [Full Text] [PDF]

				L. M. Herbert, J. F. Grosso, M. Dorsey Jr., T. Fu, I. Keydar, M. A. Cejas, D. H. Wreschner, N. Smorodinski, and D. M. Lopez A Unique Mucin Immunoenhancing Peptide with Antitumor Properties Cancer Res., November 1, 2004; 64(21): 8077 - 8084. [Abstract] [Full Text] [PDF]

				E. A. Danna, P. Sinha, M. Gilbert, V. K. Clements, B. A. Pulaski, and S. Ostrand-Rosenberg Surgical Removal of Primary Tumor Reverses Tumor-Induced Immunosuppression Despite the Presence of Metastatic Disease Cancer Res., March 15, 2004; 64(6): 2205 - 2211. [Abstract] [Full Text] [PDF]

				I. Espinoza-Delgado Cancer Vaccines Oncologist, August 1, 2002; 7(90003): 20 - 33. [Abstract] [Full Text] [PDF]

				A. D. Higgins, M. A. Mihalyo, P. W. McGary, and A. J. Adler CD4 Cell Priming and Tolerization Are Differentially Programmed by APCs upon Initial Engagement J. Immunol., June 1, 2002; 168(11): 5573 - 5581. [Abstract] [Full Text] [PDF]

				E. M. Sotomayor, I. Borrello, F.-M. Rattis, A. G. Cuenca, J. Abrams, K. Staveley-O'Carroll, and H. I. Levitsky Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression Blood, August 15, 2001; 98(4): 1070 - 1077. [Abstract] [Full Text] [PDF]

				D. I. Gabrilovich, M. P. Velders, E. M. Sotomayor, and W. M. Kast Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells J. Immunol., May 1, 2001; 166(9): 5398 - 5406. [Abstract] [Full Text] [PDF]

				S. Salvadori, G. Martinelli, and K. Zier Resection of Solid Tumors Reverses T Cell Defects and Restores Protective Immunity J. Immunol., February 15, 2000; 164(4): 2214 - 2220. [Abstract] [Full Text] [PDF]

				M. Otsuji, Y. Kimura, T. Aoe, Y. Okamoto, and T. Saito Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta  chain of T-cell receptor complex and antigen-specific T-cell responses PNAS, November 12, 1996; 93(23): 13119 - 13124. [Abstract] [Full Text] [PDF]